Pregled bibliografske jedinice broj: 1281376
Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases
Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases // Hepatology (Baltimore, Md.), 75 (2022), 1; 219-228 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1281376 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Population screening for liver fibrosis: Toward
early diagnosis and intervention for chronic liver
diseases
Autori
Gines, Pere ; Castera, Laurent ; Lammert, Frank ; Graupera, Isabel ; Serra-Burriel, Miquel ; Allen, Alina M. ; Wong, Vincent Wai-Sun ; Hartmann, Phillipp ; Thiele, Maja ; Caballeria, Llorenc ; de Knegt, Robert J. ; Grgurevic, Ivica ; Augustin, Salvador ; Tsochatzis, Emmanuel A. ; Schattenberg, Jorn M. ; Guha, Indra Neil ; Martini, Andrea ; Morillas, Rosa M. ; Garcia-Retortillo, Montserrat ; de Koning, Harry J. ; Fabrellas, Nuria ; Pich, Judit ; Ma, Ann T. ; Diaz, M. Alba ; Roulot, Dominique ; Newsome, Philip N. ; Manns, Michael ; Kamath, Patrick S. ; Krag, Aleksander
Izvornik
Hepatology (Baltimore, Md.) (0270-9139) 75
(2022), 1;
219-228
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
liver fibrosis
Sažetak
Cirrhosis, highly prevalent worldwide, develops after years of hepatic inflammation triggering progressive fibrosis. Currently, the main etiologies of cirrhosis are non-alcoholic fatty liver disease and alcohol-related liver disease, although chronic hepatitis B and C infections are still major etiological factors in some areas of the world. Recent studies have shown that liver fibrosis can be assessed with relatively high accuracy noninvasively by serological tests, transient elastography, and radiological methods. These modalities may be utilized for screening for liver fibrosis in at-risk populations. Thus far, a limited number of population-based studies using noninvasive tests in different areas of the world indicate that a significant percentage of subjects without known liver disease (around 5% in general populations and a higher rate -18% to 27%-in populations with risk factors for liver disease) have significant undetected liver fibrosis or established cirrhosis. Larger international studies are required to show the harms and benefits before concluding that screening for liver fibrosis should be applied to populations at risk for chronic liver diseases. Screening for liver fibrosis has the potential for changing the current approach from diagnosing chronic liver diseases late when patients have already developed complications of cirrhosis to diagnosing liver fibrosis in asymptomatic subjects providing the opportunity of preventing disease progression.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
Klinička bolnica "Dubrava"
Profili:
Ivica Grgurević
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE